(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2020 (13.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/163747 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61P 31/20* (2006.01)
A61K 31/713 (2006.01) *A61P 1/16* (2006.01)
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2020/017264

(22) International Filing Date:
07 February 2020 (07.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/802,614	07 February 2019 (07.02.2019)	US
62/853,659	28 May 2019 (28.05.2019)	US
62/932,315	07 November 2019 (07.11.2019)	US

(71) Applicants: **ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US). **JANSSEN PHARMACEUTICALS, INC.** [US/US]; 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

(72) Inventors: **GIVEN, Bruce D.**; c/o Arrowhead Pharmaceuticals, Inc., 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US). **HAMILTON, James C.**; c/o Arrowhead Pharmaceuticals, Inc., 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US). **SCHLUEP, Thomas**; c/o Arrowhead Pharmaceuticals, Inc., 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US). **BEUMONT-MAUVIEL, Maria**; c/o Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US). **LENZ, Oliver**; c/o Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US). **KALMEIJER, Ronald**; c/o Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

(74) Agent: **WEINER, Ethan M.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/163747 A1

(54) Title: RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION

(57) Abstract: Described are methods for inhibition of Hepatitis B virus gene expression or treating symptoms and/or diseases associated with Hepatitis B virus infection. Dosing regimens for administering these RNAi agents are also described. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B vims gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.